Logo
x

Search

Subscribe Now

CSL

PharmaShots Weekly Snapshots (February 12 – February 16, 2024)

PharmaShots Weekly Snapshots (February 12 – February 16, 2024)

  • February 16, 2024
CSL Reports Top-line Data from the P-III (AEGIS-II) Study of CSL112 for Acute Myocardial Infarction (AMI)

CSL Reports Top-line Data from the P-III (AEGIS-II) Study of CSL112 for Acute Myocardial Infarction (AMI)

  • February 12, 2024
CSL & Arcturus Therapeutics Receives MHLW Approval for ARCT-154 to Treat COVID in Adults

CSL & Arcturus Therapeutics Receives MHLW Approval for ARCT-154 to Treat COVID in Adults

  • November 29, 2023
CSL’s Hemgenix (etranacogene dezaparvovec) Receives EC’s Conditional Marketing Authorization for Hemophilia B

CSL’s Hemgenix (etranacogene dezaparvovec) Receives EC’s Conditional Marketing Authorization for Hemophilia B

  • February 21, 2023
CSL’s Hemgenix (etranacogene dezaparvovec-drlb) Receives the US FDA’s Approval for the Treatment of Hemophilia B

CSL’s Hemgenix (etranacogene dezaparvovec-drlb) Receives the US FDA’s Approval for the Treatment of Hemophilia B

  • December 22, 2022
CSL to Acquire Vifor Pharma for ~$11.7B

CSL to Acquire Vifor Pharma for ~$11.7B

  • December 15, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.